Anti-Takeover Defenses Explained — Poison Pills, Golden Parachutes, and Why Korea Has Neither

Once Treasury Shares Have to Be Retired, What's Left to Defend With?

In February 2026, South Korea's National Assembly passed a third round of amendments to the Commercial Act requiring listed companies to retire (cancel) their treasury shares within a set window after buying them back. As covered in the treasury-stock magic lesson, treasury shares have been used to entrench controlling shareholders — but they've also been, in practice, the only real anti-takeover tool available to Korean companies. A company could quietly build up a treasury-share position and later hand it to a friendly party to tip the balance in a voting fight. Once that stock has to be retired instead of held, that defensive function disappears along with it. The moment the amendment passed, Korean business groups started pushing back: if treasury shares — the one shield companies actually had — are being taken away, shouldn't there be a replacement? The tool most often named as that replacement is the poison pill, a defense widely used by U.S. companies. This lesson walks through exactly how a poison pill works, how it differs from other defenses like golden parachutes, white knights, and greenmail, and why Korea still hasn't been able to adopt one.

What a Poison Pill Actually Is — Cheap Shares for Everyone Except the Acquirer

The formal name for a poison pill is a shareholder rights plan. Here's the mechanism: it sits dormant, doing nothing, until a specific trigger fires — typically when a shareholder (or a group acting together) crosses a set ownership threshold, often somewhere around 15–20%, without the board's blessing. The instant that threshold is crossed, the plan "flips on," and every shareholder except the acquirer gets the right to buy new shares at a steep discount to market price. If enough of those shareholders exercise that right, the company's total share count balloons — but since the acquirer doesn't get that same right, their existing stake gets diluted relative to everyone else's. An acquirer who spent real money and effort accumulating shares suddenly finds their voting power cut sharply, without having done anything wrong themselves.

The mechanism splits into two variants. A flip-in provision triggers when the acquirer crosses the threshold without board approval, letting other shareholders buy discounted shares of the target company itself. A flip-over provision kicks in if the acquirer manages to push a merger through anyway — it lets other shareholders buy shares of the surviving (acquirer's) company at half price. Both versions serve the same goal: not to make a hostile takeover literally impossible, but to make it so expensive and disadvantageous that the acquirer has no real choice but to sit down and negotiate with the board instead. Notably, U.S. companies that adopt poison pills almost always build in a board power to redeem — that is, unilaterally cancel — the plan whenever directors decide a deal is actually in the company's interest. That's the real point of a poison pill: not the dilution itself, but the leverage it hands the board at the negotiating table.

A Worked Example of the Dilution

Take a hypothetical company, Company Y, with 10 million shares outstanding. Its charter includes a rights plan that triggers if any shareholder crosses 15% ownership without board consent — and once triggered, every other shareholder gets the right to buy one new share for every share they already hold, at half the market price. An acquirer, Buyer B, quietly accumulates 2 million shares (20%) on the open market, crossing the 15% trigger.

	Shares before trigger	Ownership before trigger
Buyer B	2,000,000	20%
All other shareholders	8,000,000	80%
Total	10,000,000	100%

Once the plan triggers, all 8 million shares held by everyone else become eligible to buy one new share each at half price. Assume all of them exercise the right — that adds 8 million new shares to the count.

	Shares after trigger	Ownership after trigger
Buyer B	2,000,000	~11.1%
All other shareholders	16,000,000	~88.9%
Total	18,000,000	100%

Buyer B didn't sell a single share, yet their stake fell from 20% to about 11.1%. Everyone else, meanwhile, just bought shares at half the market price — no one but Buyer B actually loses economically. That asymmetry is the entire point of the design. Faced with dilution this severe, an acquirer either has to pour in far more capital than originally planned to fight back toward a controlling stake, or — far more often — walk away from the open-market approach and come to the board's table instead.

Why Korea Doesn't Have Poison Pills — a Clash With Shareholder Equality

Most U.S. states, Delaware included, give corporate boards broad discretion under their corporate law, which is why adopting a poison pill through a simple charter provision or board resolution has been legally straightforward there for decades. Korean corporate and capital-markets law, by contrast, is built around the principle of shareholder equality — shareholders holding the same class of stock must be treated identically by the company. A poison pill, by definition, does the opposite: it hands cheap new shares to every shareholder except one, named specifically because of who they are. That's a direct conflict with the equality principle, and getting around it isn't something a company can do on its own — it requires the legislature to carve out an explicit statutory exception.

This isn't a new debate. Korea's Ministry of Justice actually pre-announced a bill back in 2009 that would have let companies adopt poison pills through board resolution alone, and that draft is still regarded as the most carefully constructed version of the idea to date — but it never cleared the National Assembly and was eventually shelved. Business groups have periodically renewed the push since then, and the discussion resurfaced again in both 2025 and 2026 among lawmakers and the Ministry of Justice. As of this writing, though, no bill that actually introduces a poison pill system has passed. The third round of Commercial Act amendments that passed in February 2026 was about mandatory treasury-share retirement — a separate piece of legislation entirely, not a poison pill law. In effect, Korean companies are caught in a gap: their old shield (treasury shares) has just gotten thinner, and the new one (a poison pill) hasn't been issued yet.

Beyond Poison Pills — Golden Parachutes, White Knights, Greenmail

A poison pill works through share dilution. Other defenses work through entirely different mechanics.

A golden parachute is a clause, written into a charter or executive contracts in advance, that guarantees departing executives a large severance payment if control of the company changes hands. Every time an acquirer wants to replace incumbent management after a takeover, they have to absorb that extra cost — which makes the whole deal less attractive. The catch is that an oversized golden parachute draws its own criticism: it can look less like protecting the company and more like management protecting its own payout.

A white knight defense is when a company under hostile-takeover threat goes looking for its own friendly third-party investor, then hands that ally shares or a favorable stake so the friendly side's voting power outweighs the hostile bidder's. Unlike a poison pill, this doesn't require any change in law — it's simply a negotiated transaction the company arranges on its own, which is exactly why it's used in real Korean control disputes today, unlike the poison pill.

Greenmail is less a defense than a threat wearing a defense's clothing. Here, the party accumulating shares was never really trying to take over the company in the first place — the goal is to pressure the company (or its controlling shareholder) into buying back that stake at a price well above market, and pocket the difference. The threat does go away the moment the company pays up, but it comes at the cost of using company money to hand one shareholder a premium that everyone else doesn't get — which is exactly why it draws criticism from the shareholders left out of the deal.

Dual-class share structures — where certain shares carry outsized voting power regardless of economic stake — and the treasury-share tactics covered earlier also count as anti-takeover tools in the broad sense. But they sit in a different category from poison pills and white knights: dual-class structures are a permanent, built-in shield baked into the company from the start, while poison pills and white knights are reactive tools deployed only once an actual threat materializes.

Comparing the Defenses

	How it works	When it activates	Status in Korea
Poison pill	Discounted new shares to everyone but the acquirer, diluting their stake	Auto-triggers at an ownership threshold	Not legal (requires new legislation)
Golden parachute	Mandatory large severance if control changes	Once a change of control is finalized	Legal via charter/contract; used in practice
White knight	Shares/stake handed to a friendly third party	Negotiated case-by-case when threatened	Not a formal legal tool — a negotiated deal, used in practice
Greenmail	Accumulate shares, then pressure a buyback at a premium	Whenever the accumulator demands it	Not a formal tool — the company decides case-by-case whether to pay
Dual-class shares	Certain shares carry outsized votes	Permanent, built into the structure	Allowed only narrowly, for unlisted venture-company founders

What Investors Should Check

If you're following a stock caught up in a control dispute or hostile-takeover story, the first thing to check is what defenses that specific company actually has available. For a Korean listed company, a poison pill simply isn't on the table — so what matters instead is how much treasury stock it holds (keeping in mind the new retirement mandate), whether its charter includes a golden parachute clause, and whether the controlling shareholder has a realistic path to lining up a white knight. For a U.S. listed company, the key variables flip: whether a poison pill is in place at all, and where its trigger threshold is set. A lower threshold gives the board more defensive leverage, but it can also block perfectly ordinary large purchases — say, a friendly institutional investor building a bigger position — which is exactly why trigger thresholds themselves become a shareholder-value debate in the U.S. context. Finally, since Korea's poison-pill debate is still an active, unresolved policy question as of this writing, anyone making decisions based on it should check the latest word from the National Assembly and Ministry of Justice rather than treating anything here as settled law.

Takeaways

• A poison pill (shareholder rights plan) triggers automatically once an acquirer crosses a set ownership threshold, giving every other shareholder the right to buy discounted new shares — diluting the acquirer's stake without them doing anything else wrong.
• The two variants are flip-in (discounted shares of the target itself) and flip-over (discounted shares of the surviving company after a merger).
• Korea has never adopted a poison pill, because it directly conflicts with the shareholder-equality principle in Korean corporate law; a 2009 Ministry of Justice bill never passed, and the debate has resurfaced now that mandatory treasury-share retirement (February 2026) has weakened companies' one existing defense.
• Golden parachutes, white knights, and greenmail work through entirely different mechanics — severance cost, friendly-stake accumulation, and buyback pressure, respectively — rather than share dilution.
• Understanding which specific defenses a company you're invested in actually has access to, and where Korea's poison-pill legislation currently stands, is the starting point for making sense of any control-dispute headline.

FAQ

If Korea adopted poison pills, would that end hostile takeovers entirely?

No. A poison pill doesn't make a hostile takeover impossible — it makes it much more expensive and disadvantageous, pushing the acquirer toward negotiating with the board instead. An acquirer with enough capital and determination can still push through despite the dilution, and a board can always redeem (cancel) the plan itself if it decides a deal is actually worth accepting.

Can a Korean company just write a poison pill clause into its own charter?

No. Because a poison pill by definition excludes one specific shareholder (the acquirer) from a benefit given to everyone else, it directly conflicts with the shareholder-equality principle embedded in Korean corporate and capital-markets law. A company can't simply legislate around that on its own — an explicit statutory exception would have to be created first.

How is mandatory treasury-share retirement connected to the poison-pill debate?

Treasury shares have functioned as Korean companies' de facto only anti-takeover tool. The February 2026 Commercial Act amendment requiring those shares to be retired weakened that defense, and business groups are now pushing harder for a poison pill to fill the resulting gap. As of this writing, though, no legislation actually introducing a poison pill has been passed.

⚠️ This article is for informational purposes only and is not investment advice. Korea's poison-pill debate discussed here remains an active, unresolved policy question as of this writing, and the actual legislative outcome and its details may change. You are solely responsible for your own investment decisions and their outcomes.